READ CEO INTERVIEWS
Featured
Quenching Global Demand: How Nerovate Is Using AI and Lean Principles to Revolutionize Water Management
With over 25 years in digital transformation, Victor AbouRahal is setting his sights on wringing out wasted water costs.
Onyx @ Union Square: Shankar Musunuri, Ocugen
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
Onyx @ Union Square: Mike Exton, Lexicon Pharmaceuticals
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
The future of fluorescence is smaller, smarter, and more accessible
FLIM LABS is redesigning the tools of fluorescence-lifetime imaging to enable broader access across medicine, pharma, and environmental science.
Onyx Studio Sessions: Paula Brown Stafford, Allucent
Allucent are helping small- to mid-sized biotechs stay nimble.
Milliseconds Matter: How Wärtsilä’s Battery Tech Is Reinventing Grid Reliability
From ship engines to smart batteries, 190-year-old Wärtsilä has reinvented itself as an energy storage powerhouse with lightning-fast speeds.
Is COP a flop?
The UN climate conference and its chequered history with the United States
Quenching Global Demand: How Nerovate Is Using AI and Lean Principles to Revolutionize Water Management
With over 25 years in digital transformation, Victor AbouRahal is setting his sights on wringing out wasted water costs.
Hydro-Québec's energy storage spin-out EVLO might be key to a more reliable grid
“The energy transition isn’t just my job—it’s what drives me,” How Sonia St-Arnaud is tackling one of the biggest challenges in clean power.
Milliseconds Matter: How Wärtsilä’s Battery Tech Is Reinventing Grid Reliability
From ship engines to smart batteries, 190-year-old Wärtsilä has reinvented itself as an energy storage powerhouse with lightning-fast speeds.
Quenching Global Demand: How Nerovate Is Using AI and Lean Principles to Revolutionize Water Management
With over 25 years in digital transformation, Victor AbouRahal is setting his sights on wringing out wasted water costs.
Hydro-Québec's energy storage spin-out EVLO might be key to a more reliable grid
“The energy transition isn’t just my job—it’s what drives me,” How Sonia St-Arnaud is tackling one of the biggest challenges in clean power.
Onyx @ Union Square: Shankar Musunuri, Ocugen
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
Onyx @ Union Square: Mike Exton, Lexicon Pharmaceuticals
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
Onyx Studio Sessions: Paula Brown Stafford, Allucent
Allucent are helping small- to mid-sized biotechs stay nimble.
Onyx @ Union Square: Colleen Cutcliffe, Pendulum
Ever thought a probiotic could help manage blood sugar by stimulating GLP-1?
"It's like Duolingo for sewing" - how Della Yellow is ushering in the age of circular fashion
A digital community for clothing repairs has high hopes to upskill consumers worldwide and trigger an upcycle revolution.
How Piramal Pharma plans to become a multi-billion dollar business
Peter DeYoung lends insights on the strategic approach behind Piramal Phama’s expansion and growth.
We all want our hospital records in one place. Is Novellia the app to do it?
Shashi Shankar explains how his app unifies patients' scattered medical records all together, and what that has to do with the 21st Century Cures Act.
Adil's JPM Week VLOG
Join me in San Fran as I interview CEOs and reveal what Onyx has in store for readers this year.
Onyx Studio Sessions: Fabian Gerlinghaus, Cellares
Can this man bring down the cost of some of the most expensive and hope-inspiring new therapies on the market?
Backed by AstraZeneca, this company is helping radioligand cancer therapies hit the shelves
"Think of us as a critical partner in the ecosystem, ensuring that brilliant innovation doesn’t get stuck in the development phase but actually reaches the patients who need them."
Onyx @ Union Square: Helmy Eltoukhy, Guardant Health
Blood tests for cancer are here, and Guardant Health is leading the charge.
CAR-T can only treat 3% of cancer patients. Mongoose Bio is building for the other 97%
Neil Warma explains how Mongoose Bio is pioneering TCR-T therapies that may last longer, tackle more cancers, and require less from patients.
This biotech is targeting the 'immortality switch' to fight blood cancers
Harnessing Nobel Prize-winning insights on telomeres, Geron’s CEO Dr. John A. Scarlett is taking on some of hematology’s toughest challenges—and winning FDA backing in the process.
NVIDIA’s Biggest Bet Yet: How Recursion Is Powering a New Era of AI-Driven Drug Discovery
“Almost all of the data that we use comes from our own laboratories - data generation doing real experiments in human biology… The AI side of things will be commoditized eventually, and the winners will be those who have the strongest data moat in life sciences.”
From Grammys to Gene Therapy: Gaurav Shah’s Rocket-Fueled Revolution in Rare Diseases
A Grammy-winning CEO is taking gene therapy to new heights.
Is neuromodulation the breakthrough that Alzheimer's has been waiting for?
Sinaptica's precision neuromodulation combines TMS and EEG to target memory networks, offering new hope in Alzheimer's care.
Mayo Clinic-backed, Halle Berry-approved: Pendulum’s Dr. Colleen Cutcliffe is tackling type 2 diabetes before it even starts.
As clinical trials progress, Pendulum hopes their medical evidence can beat the status quo and encourage Americans to take preventative care into their own hands.